Chinese COVID-19 vaccine trial shows strong immune response in 960 volunteers

NCT ID NCT04649021

Completed ⭐️ VACCINE ⭐️ Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested the BNT162b2 mRNA vaccine in 960 healthy Chinese adults aged 18 to 85. Participants received two doses of either the vaccine or a placebo, 21 days apart. The main goal was to check safety and measure the immune response, specifically neutralizing antibodies against SARS-CoV-2. Results showed the vaccine triggered a strong antibody response, supporting its use in this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BNT162b2 mRNA vaccine
What this could lead to: If successful, this could confirm that the BNT162b2 vaccine is safe and effective for Chinese populations, supporting its use in pandemic control.
What could go wrong: This is a Phase 2 trial with 960 participants, so results may not fully predict real-world effectiveness or rare side effects. The study is completed, but long-term data are still limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV-2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease severe acute respiratory syndrome COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-COV-2

Contacts and locations

Locations

Jiangsu Provincial Center for Disease Control and Prevention

Nanjing, 210009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.